PDF: Long-Term Efficacy of Tildrakizumab in the Treatment of Psoriasis

PDF Download: A review of the long-term efficacy and safety of tildrakizumab, a monoclonal antibody targeting the IL-23/IL-17 pathway, in treating moderate-to-severe plaque psoriasis. Evidence from Phase 3 clinical trials and extension studies demonstrates that tildrakizumab is an effective and well-tolerated therapy, significantly improving skin clearance and maintaining a favorable safety profile over several years of use.
Read online:
Long-Term Efficacy of Tildrakizumab in the Treatment of Psoriasis